Cite
Ivagnès A, Messaoudene M, Stoll G, et al. TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncoimmunology. 2017;7(12):e1386826doi: 10.1080/2162402X.2017.1386826.
Ivagnès, A., Messaoudene, M., Stoll, G., Routy, B., Fluckiger, A., Yamazaki, T., Iribarren, K., Duong, C. P. M., Fend, L., Caignard, A., Cremer, I., LeCesne, A., Adam, J., Honoré, C., Mir, O., Chaigneau, L., Berger, A., Validire, P., Christidis, C., Brun-Ly, V. L., Smyth, M. J., Mariette, X., Salomon, B. L., Kroemer, G., Rusakiewicz, S., & Zitvogel, L. (2018). TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncoimmunology, 7(12), e1386826. https://doi.org/10.1080/2162402X.2017.1386826
Ivagnès, Alexandre, et al. "TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer." Oncoimmunology vol. 7,12 (2018): e1386826. doi: https://doi.org/10.1080/2162402X.2017.1386826
Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L. TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncoimmunology. 2017 Oct 11;7(12):e1386826. doi: 10.1080/2162402X.2017.1386826. eCollection 2018. PMID: 30524877; PMCID: PMC6279330.
Copy
Download .nbib